<DOC>
	<DOCNO>NCT00113594</DOCNO>
	<brief_summary>The purpose study characterize olanzapine pharmacokinetics : inter- intra- subject variability olanzapine pharmacokinetics ; potential influence patient factor age , weight , gender , origin , smoke status olanzapine pharmacokinetics adolescent schizophrenia bipolar I disorder . This study also assess safety olanzapine deliver orally .</brief_summary>
	<brief_title>Olanzapine Treated Adolescents With Schizophrenia Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Male female patient , 13 17 year age ( must reach 18th birthday prior Visit 1 ) . Female patient must pregnant nursing . Patient patient 's parent/authorized legal representative must level understanding sufficient perform test examination require protocol , must give informed consent . Patient must previously document diagnosis schizophrenia bipolar I accord DSMIVTR , either confirm previously KSADSPL confirm KSADSPL Visit 1 . Patients must experience acute , serious , unstable medical condition schizophrenia bipolar I disorder . Patients allow study currently meet criterion depress phase bipolar disorder diagnose Bipolar II Disorder .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>